The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
GCLLSG 2016 | A new prognostic tool for CLL: CLL-IPI
Jasmin Bahlo, PhD of University of Cologne, Cologne, Germany gives an overview of her talk on CLL-IPI held at the 2016 International Workshop of the German CLL Study Group (GCLLSG) in Cologne, Germany. Dr Bahlo first talks about the current standard of prognostication in chronic lymphocytic leukemia (CLL). She explains that now there are more markers available and many new discoveries have been made in genetics that need to be considered in prognostication. The IPI analysis was a comprehensive analysis that covered a broad range of variables with the aim of developing a prognostic index, which considers all factors and which can be used in clinical practice.
